Press Release

Techulon’s Platform Demonstrates Effective Non-Viral DNA Delivery for in vivo Cardiac Study
Techulon Glycopolymers Deliver NF-κB Decoy to Mitigate Injury from Cardiac Ischemia
Blacksburg, VA:  Techulon Inc., developer of low-toxicity DNA and RNA delivery technology, announced today that its platform was used successfully in a recent in vivo study focused on blocking downstream inflammatory pathways. Techulon’s polymers were used as delivery agents for an NF-κB oligodeoxynucleotide (ODN) decoy used to limit myocardial infarction during an ischemic-repurfusion event simulating a heart attack. This study compared the efficacy and toxicity of poly(glycoamidoamine)s (PGAA’s) against well known lipid and polyethyleneimine technologies for delivery of the decoy to H9c2 cells and cardiomyocytes in vitro, and to the in vivo murine heart.

The PGAA’s demonstrated superior delivery efficacy and significantly reduced toxicity over the reference delivery modes.

The paper, entitled “In Vivo Delivery of Nucleic Acids via Glycopolymer Vehicles Affords Therapeutic Infarct Size Reduction in Vivo,” was authored by Tranter, Liu, He, Gulick, Ren, Robbins, Jones and Reineke and appeared in the December 20 issue of Molecular Therapy.

Techulon holds exclusive licenses for the PGAA polymers used in the study. The company is focused on developing advanced delivery technologies for therapeutic applications.

“This study demonstrates that the PGAA polymers enabled low toxicity delivery in vivo. The most significant finding in the study was that this composition provides for much higher DNA delivery to cell nuclei in vivo than what was predicted by in vitro comparisons of the PGAAs to lipids and polyethyleneimines” said Dr. Joshua Bryson, Principal Scientist at Techulon. “This compelling study demonstrates the PGAAs to be an efficacious delivery tool offering a non-toxic vehicle for therapeutics companies.”

Techulon’s platform is designed for use by partner companies in collaboration to engineer safer, more effective cell therapies. The company provides access to the platform through licensing and collaboration arrangements.

About Techulon, Inc.:
Techulon is leading the next generation of disease treatment through development of innovative nucleic acid therapeutics. The company is headquartered in the Virginia Tech Corporate Research Center in Blacksburg and was founded in 2006 by Virginia Tech College of Science alumni with the mission to bring new technologies to intractable diseases.


Techulon Inc.
2200 Kraft Dr., Suite 2475
Blacksburg, VA 24060